- Trials with a EudraCT protocol (48)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
48 result(s) found for: Urine sediment.
Displaying page 1 of 3.
EudraCT Number: 2011-005856-32 | Sponsor Protocol Number: RITULUP | Start Date*: 2012-05-21 | |||||||||||
Sponsor Name:Fundación Progreso y Salud | |||||||||||||
Full Title: Comparison of the efficacy of two rituximab treatment regimens in patients with lupus nephropathy resistant to conventional treatment | |||||||||||||
Medical condition: Long-term relapse after treatment of lupus nephritis (LN) resistant to conventional treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002159-32 | Sponsor Protocol Number: 211LE201 | Start Date*: 2012-03-30 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects With Lupus Nephritis | |||||||||||||
Medical condition: Lupus Nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Prematurely Ended) BE (Completed) DE (Completed) ES (Prematurely Ended) HU (Completed) IT (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005979-16 | Sponsor Protocol Number: PrOvAS001 | Start Date*: 2013-04-29 |
Sponsor Name:Instituto de Investigación Sanitaria La Fe | ||
Full Title: PREECLAMPSIA OF PREVENTION IN PATIENTS THROUGH ovodonation aspirin in early gestation | ||
Medical condition: PREECLAMPSIA | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003372-73 | Sponsor Protocol Number: ZTI-01-200 | Start Date*: 2016-04-11 | ||||||||||||||||
Sponsor Name:Zavante Therapeutics, Inc. | ||||||||||||||||||
Full Title: A Multi-center, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 Versus Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, In... | ||||||||||||||||||
Medical condition: Complicated Urinary Tract Infections, Including Acute Pyelonephritis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) HU (Completed) LT (Completed) LV (Completed) SK (Completed) PL (Completed) EE (Completed) GR (Completed) BG (Completed) RO (Completed) HR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-004518-15 | Sponsor Protocol Number: 28113 | Start Date*: 2008-08-05 | |||||||||||
Sponsor Name:Merck Serono International | |||||||||||||
Full Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atacicept in Subjects with Lupus Nephritis in Combination with Mycophenolate Mofetil Therapy | |||||||||||||
Medical condition: Lupus nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002554-78 | Sponsor Protocol Number: PB-102-F02 | Start Date*: 2013-08-29 | |||||||||||
Sponsor Name:Protalix Ltd. | |||||||||||||
Full Title: An Extension of Phase 1/2, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion ... | |||||||||||||
Medical condition: Fabry disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003244-13 | Sponsor Protocol Number: D4280C00016 | Start Date*: 2015-04-17 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A single blind, randomised, multi-centre, active controlled, trial to evaluate safety, tolerability, pharmacokinetics and efficacy of ceftazidime and avibactam compared with cefepime in children fr... | |||||||||||||
Medical condition: Complicated urinary tract infections | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) GR (Completed) PL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001442-29 | Sponsor Protocol Number: D3461C00007 | Start Date*: 2016-01-14 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Proliferative Lupus Nephritis | |||||||||||||
Medical condition: Lupus Nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005609-28 | Sponsor Protocol Number: RAV-IgA | Start Date*: 2022-03-18 |
Sponsor Name:Dr. Alfons Segarra Medrano | ||
Full Title: A PILOT PROOF-OF–CONCEPT STUDY TO ASSESS THE EFFICACY AND SAFETY OF A 6 MONTHS RAVULIZUMAB TREATMENT IN PATIENTS WITH FLARES OF CORTICOSTEROID-RESISTANT IDIOPATHIC IgA NEPHROPATHY | ||
Medical condition: Treatment for IgA nephropathy flares | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-004786-40 | Sponsor Protocol Number: PB-102-F01 | Start Date*: 2013-05-10 | |||||||||||
Sponsor Name:Protalix Ltd. | |||||||||||||
Full Title: A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks ... | |||||||||||||
Medical condition: Fabry disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005357-29 | Sponsor Protocol Number: WA20500 | Start Date*: 2008-05-07 |
Sponsor Name:F. Hoffmann-La Roche Ltd | ||
Full Title: A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy and Safety of Two Doses of Ocrelizumab in Subjects With WHO or ISN Class III or IV Nephrit... | ||
Medical condition: Lupus Nephritis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) FR (Completed) DE (Completed) HU (Completed) ES (Completed) NL (Completed) PT (Prematurely Ended) SE (Completed) PL (Prematurely Ended) BG (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003211-57 | Sponsor Protocol Number: CAIN457Q12301 | Start Date*: 2020-03-26 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A two-year, phase III randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the safety, efficacy, and tolerability of 300 mg s.c. secukinumab versus placebo, in combination... | |||||||||||||
Medical condition: Lupus Nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Prematurely Ended) NO (Prematurely Ended) GB (GB - no longer in EU/EEA) PT (Prematurely Ended) DE (Completed) SE (Prematurely Ended) DK (Prematurely Ended) GR (Completed) LV (Prematurely Ended) ES (Prematurely Ended) HR (Completed) FR (Completed) IT (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015403-95 | Sponsor Protocol Number: NS10364-3 | Start Date*: 2010-02-11 |
Sponsor Name:Faculty Hospital Hradec Králové | ||
Full Title: A pilot trial of noninvasive assessment of methotrexate hepatotoxicity in the course of pharmacokinetically guided pharmacotherapy of psoriasis with methotrexate and folic acid | ||
Medical condition: moderate-severe and severe plaque psoriasis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002608-29 | Sponsor Protocol Number: CS2514-2017-0003 | Start Date*: 2017-12-12 | ||||||||||||||||
Sponsor Name:Entasis Therapeutics | ||||||||||||||||||
Full Title: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infe... | ||||||||||||||||||
Medical condition: Complicated Urinary Tract Infection including Acute Pyelonephritis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000714-11 | Sponsor Protocol Number: IM101-291 | Start Date*: 2013-04-20 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil (MMF) and Corticostero... | |||||||||||||
Medical condition: Active Class III or IV lupus glomerulonephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) CZ (Completed) ES (Completed) RO (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004917-41 | Sponsor Protocol Number: WX17801 | Start Date*: 2005-09-05 | |||||||||||
Sponsor Name:Aspreva International Ltd. | |||||||||||||
Full Title: A prospective, randomized, active controlled, parallel group, multi-center trial to assess the efficacy and safety of mycophenolate mofetil (MMF) in inducing response and maintaining remission in s... | |||||||||||||
Medical condition: Lupus Nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) HU (Completed) CZ (Completed) ES (Completed) BE (Completed) PT (Completed) AT (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022096-54 | Sponsor Protocol Number: Repha_1344 | Start Date*: 2011-04-04 | |||||||||||
Sponsor Name:Repha GmbH | |||||||||||||
Full Title: Randomised, prospective, double-dummy double-blinded study to evaluate safety and efficacy of Angocin Anti-Infekt N versus standard antibiotics in the treatment of acute uncomplicated cystitis | |||||||||||||
Medical condition: Treatment of acute uncomplicated cystitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002221-36 | Sponsor Protocol Number: 28779 | Start Date*: 2008-10-17 | |||||||||||
Sponsor Name:Merck Serono International, An affiliate of Merck KGaA, Darmstadt, Germany | |||||||||||||
Full Title: A Phase II/III, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of atacicept in combination with corticosteroids and sequential therapy with cyclophosphamide ... | |||||||||||||
Medical condition: Lupus Nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005117-31 | Sponsor Protocol Number: W-4282-301 | Start Date*: 2018-10-17 | ||||||||||||||||
Sponsor Name:Wockhardt Bio AG | ||||||||||||||||||
Full Title: A Phase III, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-Tazobactam vs. Meropenem followed by Optional Oral Therapy in the Treatment of... | ||||||||||||||||||
Medical condition: Complicated urinary tract infection or acute pyelonephritis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Temporarily Halted) BG (Temporarily Halted) LV (Completed) LT (Temporarily Halted) PL (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003671-35 | Sponsor Protocol Number: SPR994-301 | Start Date*: 2019-04-18 | |||||||||||
Sponsor Name:Spero Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) ... | |||||||||||||
Medical condition: complicated urinary tract infection or acute pyelonephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LV (Completed) BG (Completed) HU (Completed) PL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
